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ABSTRACT (248/250 words) 48 
Objective. To examine the association of blood pressure with cardiovascular mortality 49 
in real-world settings and investigate whether that association varied by use of 50 
antihypertensive medication at baseline.  51 
Methods. Data from 27,728 Japanese men and women, aged 40-79 years, free of stroke, 52 
coronary heart disease, cancer, and kidney disease at entry (1988-1990) were used in 53 
this study. Mortality surveillance was completed through 2009, resulting 449,800 54 
person-year follow-up. Hazard ratios for cardiovascular mortality were analysed by 55 
blood pressure category (based on 2018 European guidelines) at admission.  56 
Results. There were 1,477 deaths from cardiovascular diseases. Relative to high-normal 57 
blood pressure at admission, the multivariable hazard ratios (95% confidence intervals) 58 
of cardiovascular disease were: 0.85(0.69-1.04) for optimal blood pressure; 59 
0.96(0.81-1.15) for normal blood pressure; 1.26(1.09-1.46) for Grade 1 hypertension; 60 
and 1.55(1.31-1.84) for Grade 2-3 hypertension. A similar linear association was 61 
observed among persons not taking antihypertensive medication at admission. Among 62 
patients treated for hypertension, a U-shaped association with cardiovascular disease 63 
mortality was observed; hazard ratios =2.31(1.25-4.27), 1.68(1.05-2.69), 64 
1.56(1.10-2.22), and1.63 (1.13-2.36), respectively. Similar patterns were observed for 65 
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stroke and coronary heart disease, although not always statistically significant.  66 
Conclusions. Blood pressure categories at baseline were linearly and positively 67 
associated with cardiovascular disease mortality overall and also among participants not 68 
taking antihypertensive medication. A higher risk of mortality from cardiovascular 69 
disease was observed among patients already treated for hypertension with optimal and 70 
normal blood pressures than those with high-normal blood pressure, suggesting the 71 
importance of careful monitoring of blood pressure and comorbidities of such patients. 72 
 73 
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Introduction 75 
It is well known that high blood pressure (BP) increases the risk of cardiovascular 76 
disease (CVD) [1], and that treatment of hypertension reduces that risk [2]. Clinical 77 
trials have shown that treating hypertension to below-normal BP levels is better for the 78 
prevention of coronary heart disease or stroke among patients with high cardiovascular 79 
risk [3]. On the other hand, several prospective cohort studies have shown that among 80 
patients treated for hypertension treatment to low BP levels was associated with 81 
increased risk of coronary heart disease and/or stroke compared with treatment to 82 
moderate BP levels [4-8]. 83 
 The causal relations need to be determined through randomized controlled 84 
trials, as observational study designs have inevitable drawbacks (eg confounding 85 
factors). As mentioned, some clinical trials have shown the benefit of lowering BP 86 
below ‘normal’ levels among strictly selected patients [3]. However, in general practice, 87 
patients with hypertension alongside comorbidities such as atherosclerosis, atrial 88 
fibrillation, and heart failure are sometimes unintentionally treated to low BP levels, 89 
which could lead to an elevated risk of CVD. Clinical trials are typically performed 90 
under ‘ideal’ trial conditions (following strict inclusion/exclusion criteria and a rigid 91 
protocol), and their results may not be generalizable to general practice where patients 92 
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might exhibit hypertension together with such comorbidities as mentioned above. In 93 
addition, many trials, such as the Action to Control Cardiovascular Risk in Diabetes 94 
(ACCORD) [9] or the Systolic Blood Pressure Intervention Trial (SPRINT) [10], with 95 
careful monitoring of adverse events, involved patients with diabetes mellitus (DM) or 96 
high cardiovascular risk. However, despite the possibility of confounding, results from 97 
observational studies of the general population may better reflect clinical realities. 98 
Therefore, the objective of the current study is to provide reliable information 99 
on the relationship between baseline BP levels and long-term mortality from CVD in a 100 
large sample and use differential analysis to examine whether the association varied by 101 
antihypertensive medication use. Our intention is not to try to prove or disprove whether 102 
hypertension should be treated aggressively, but rather to shed light on the outcomes of 103 
patients treated for hypertension in a general (Asian) population.  104 
 105 
Methods 106 
Study Cohort and Baseline Questionnaire 107 
Data of the Japan Collaborative Cohort Study for Evaluation of Cancer Risk 108 
(JACC Study), a large nationwide community-based prospective study of Japanese 109 
women and men, were used in our analysis. The JACC study was initiated in 1988-1990, 110 
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and involved 110,585 individuals (46,395 men and 64,190 women) aged 40 to 79 years 111 
living in 45 communities across Japan, who participated in municipal health screening 112 
examinations and completed self-administered questionnaires about their lifestyles and 113 
medical histories of previous CVD and cancer [11]. Prior to completing the 114 
questionnaire, the participants or community representatives provided informed consent 115 
to be involved in this epidemiological study, based on guidelines of the Council for 116 
International Organizations of Medical Science [12]. The JACC Study protocol was 117 
approved by the institutional review boards of Hokkaido University, Osaka University, 118 
and the University of Tsukuba.  119 
Data on blood pressure were available for 29,928 individuals (10,884 men and 120 
19,044 women) from 30 communities who participated in health examinations 121 
conducted by municipal governments. After excluding 2,200 individuals from the 122 
analysis because of previous history of stroke, coronary heart disease, cancer, or kidney 123 
disease at the time of baseline inquiry, 27,728 individuals (10,091 men and 17,637 124 
women) were included in the study.  125 
Baseline BP was measured as a part of health screening examinations. As standard, 126 
BP was measured by trained observers using standard mercury sphygmomanometer on 127 
the right arm of seated participants after 5 minutes rest. The modified classification of 128 
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BP from the 2018 European Society of Hypertension-European Society of Cardiology 129 
guidelines [13] was used for classisification. The optimal BP was defined as systolic 130 
pressure <120 mmHg and diastolic pressure <80 mmHg; normal BP as systolic pressure 131 
<130 mmHg and diastolic pressure <85 mmHg; high-normal BP as systolic pressure 132 
130-139 mmHg or diastolic pressure 85-89 mmHg; Grade 1 hypertension as systolic 133 
pressure 140-159 mmHg or diastolic pressure 90-99 mmHg; Grade 2 hypertension as 134 
systolic pressure 160-179 mmHg or diastolic pressure 100-109 mmHg; and Grade 3 135 
hypertension as systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg. 136 
Information on antihypertensive medication use and history of DM diagnosis were 137 
obtained from questionnaires.  138 
 139 
Mortality Surveillance 140 
To ascertain deaths among the cohort, a systematic review of death certificates, all of 141 
which were forwarded to the local public health centre in each community was 142 
conducted. It is believed that all cohort deaths were recorded, except for those 143 
participants who died after moving from their original community, in which case the 144 
participants’ data were censored. The date of moving from the community was verified 145 
using population-registration documents. Mortality data were sent centrally to the 146 
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Ministry of Health and Welfare, and the underlying cause of death was coded for 147 
National Vital Statistics according to the International Classification of Disease, 10th 148 
Revision. The mortality follow-up continued through 2009 (except for 3 communities 149 
censored at the end of 1999, 1 community at the end of 2003, and 2 communities at the 150 
end of 2008). The median follow-up was 18.5 years. 151 
 152 
Statistical Analysis 153 
Person-years of follow-up were calculated from the date of the baseline questionnaire to 154 
the date of death, emigration from the community, or the end of 2009 (or 1999, 2003, 155 
2008), whichever occurred first. The BP exposure was analysed using the 5 categories 156 
of the 2018 European Society of Hypertension-European Society of Cardiology [13]. 157 
Because of the relatively low percentage of the categories of individuals with Grade 3 158 
hypertension, the categories of Grade 2 and Grade 3 hypertension were combined. The 159 
category of high-normal BP was used as the reference. 160 
Age-adjusted means and proportions of selected cardiovascular risk factors were 161 
compared across the categories of BP. Cox proportional hazards model were used to 162 
calculate the age-, sex-, and multivariable-adjusted hazard ratios (HR) and 95% 163 
confidence intervals (CI), by stratification for area (7 regional classifications commonly 164 
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used in Japan: Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, and Kyushu). 165 
Adjusting factors included body mass index (kg/m2, sex-specific quartiles), total 166 
cholesterol levels (mmol/L, sex-specific quartiles), history of DM (yes versus no), 167 
history of kidney diseases (yes versus no), smoking status (never, ex-smoker, or current 168 
smoker of 1-19 and ≥20 cigarettes per day), and alcohol intake category (never, 169 
ex-drinker, and current drinker at 1-45 and ≥46g ethanol per day). Cardiovascular 170 
mortality as the underlying cause included: stroke (International Classification of 171 
Disease, 10th Revision, codes I60 to I69), coronary heart disease (codes I20 to I25) and 172 
total CVD (codes I01 to I99). We confirmed that there was no violation of the 173 
proportional hazards assumption. 174 
175 
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Results 176 
The overall prevalence of hypertension (systolic BP ≥140 mmHg and/or diastolic BP 177 
≥90 mmHg and/or use of antihypertensive medication) in this population was 42.3%. As 178 
Table 1 shows, the prevalence of anti-hypertensive medication use, DM, and currently 179 
drinking, and the mean values of total cholesterol and body mass index were higher in 180 
persons with Grade 2-3 hypertension than those with lower BP.  181 
During the maximum of 21.6 (median 18.5) years of follow-up of 27,728 182 
individuals aged 40 to 79 years, 5,239 participants died and 1,309 participants had 183 
relocated. The fatalities included 1,477 deaths from CVD; 682 deaths from stroke and 184 
304 deaths from coronary heart disease.  185 
The Figure shows the crude mortality rate, and Table 2 shows 186 
multivariable-adjusted HRs of total CVD mortality according to baseline BP category. 187 
The crude cardiovascular mortality rates, in all baseline BP categories, were higher 188 
among patients treated for hypertension than those untreated (Figure), implying that 189 
treated patients already had higher a risk at baseline. As shown in Table 2, higher BP 190 
categories were associated linearly and positively with risk of CVD mortality. Relative 191 
to high-normal BP, the multivariable HRs were 0.85 (95% CI: 0.69-1.04) for optimal 192 
BP, 0.96 (0.81-1.15) for normal BP, 1.26 (1.09-1.46) for Grade 1 hypertension, and 1.55 193 
 
- 13 - 
(1.31-1.84) for Grade 2-3 hypertension. A similar linear association was observed 194 
among persons with no baseline antihypertensive medication use. Among those treated 195 
for hypertension at baseline, however, a U-shaped association with CVD mortality was 196 
observed. The multivariable HRs were: 2.31 (1.25-4.27), 1.68 (1.05-2.69), 1.56 197 
(1.10-2.22), and 1.63 (1.13-2.36), respectively. Similar relations, but not always 198 
statistically significant, were separately observed for stroke and coronary heart disease 199 
(Supplemental Table). These trends were essentially similar when men and women were 200 
analysed separately (not shown in tables).  201 
  202 
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Discussion 203 
In this large and long-term prospective cohort study of a Japanese general population 204 
aged 40-79 years, we confirmed a linear relation between higher BP category at baseline 205 
and risk of total CVD mortality. On the other hand, among participants treated for 206 
hypertension, we found a U-shaped relation with a nadir at high-normal BP. That 207 
association was similarly observed for mortality from stroke and coronary heart disease. 208 
The high mortality among patients with hypertension treated to below normal BP levels 209 
is unlikely to be causal, due to the ‘real-life’ nature of the observational data used in our 210 
study. Our findings suggest the importance of careful monitoring of BP and 211 
comorbidities of patients already undergoing treatment for hypertension who have low 212 
BP levels at initial presentation, which is in line with the European Guidelines for the 213 
management of arterial hypertension recommendations which state: “Importantly, the 214 
impact of BP-lowering on the well being of the patient should be closely monitored, 215 
because the increased risk of adverse events (e.g. injurious falls) with lower BP values 216 
could be more pronounced in older patients in the real-life setting than in the closely 217 
monitored conditions of randomized controlled trials”.[13] 218 
A recent study pooling 2 randomized controlled trials (SPRINT and ACCORD) 219 
demonstrated that intensive treatment targeting <120 mmHg systolic BP significantly 220 
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lowered risk of CVD mortality (HR = 0.83 [0.74-0.92]) compared to standard treatment 221 
targeting <140 mmHg [3]. A network meta-analysis of 42 trials including 144,220 222 
patients found the lowest incidence and mortality from CVD in the 120 to 124 mmHg 223 
systolic BP category compared with the higher categories, although they did not 224 
examine the risk below 120 mmHg [14]. Our results do not conflict with the results of 225 
these trials. The purpose of the clinical trials was to prove the benefit of BP-lowering 226 
treatment among high-risk patients under ideal clinical trial conditions. For example, 227 
participants in SPRINT were required to have an increased risk of CVD, such as clinical 228 
or subclinical CVD (except for stroke), chronic kidney disease, high Framingham risk 229 
score, or age of 75 years or older [10]. In that trial, patients who had DM or a history of 230 
stroke were excluded. Participants in ACCORD all had DM, and one of the following: 231 
CVD, anatomical evidence of atherosclerosis, albuminuria, left ventricular hypertrophy, 232 
or at least 2 conventional cardiovascular risk factors (dyslipidemia, hypertension, 233 
smoking, or obesity) [9]. The purpose of these trials was to explore the effect of 234 
intensive BP lowering in high-risk patients. On the other hand, observational studies, by 235 
their nature, cannot prove causality or address the optimal level to reduce high BP, but 236 
may more accurately reflect the clinical reality. Patients treated for hypertension to low 237 
BP levels may have had a higher prevalence of end-organ defects such as carotid 238 
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atherosclerosis, cardiac hypertrophy, or chronic kidney disease and, thus, carried a 239 
higher risk of CVD. Physicians were likely to aggressively treat hypertension in those 240 
patients. However at the baseline of this study (1988-1990), under the criteria of 241 
hypertension of ≥160/95 mmHg, the aggressive treatment of hypertension was less 242 
common in general practice than it is nowadays. Rather, in general practice, 243 
hypertension is typically treated by physicians who are not necessarily experts of 244 
cardiology. Patients treated for hypertension may have comorbidities that are likely 245 
cause low BP such as atherosclerosis, atrial fibrillation, or heart failure. These patients 246 
are sometimes unintentionally treated to below normal BP levels, in which the risk of 247 
mortality from CVD increases.  248 
As stated, observational data and clinical trial data both have their advantages and 249 
disadvantages. Our observational data perhaps more accurately reflect the natural course 250 
of a general community-dwelling population, whereas clinical trial data involves a more 251 
selected sample of patients who met certain inclusion/exclusion criteria. Accordingly, 252 
observational data cannot prove the causality while the trial data have restrictions in 253 
terms of generalizability. The U-shape associations among patients already treated for 254 
hypertension in the present study do not disprove the beneficial effect of 255 
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anti-hypertensive medication, but do shed light on the long-term outcomes of patients 256 
with hypertension who were under treatment at baseline. 257 
Further limitations of the present study should be noted. First, the information on 258 
BP and antihypertensive medication use was obtained at baseline only, and thus changes 259 
in BP and continued medication use were not taken into account. The nature of the 260 
observational study does not allow for controlling variables that may influence 261 
behaviour. Second, while we had information on current antihypertensive medication 262 
use at baseline, we had no information on the type, dosage, and duration of the drugs 263 
prescribed at and after baseline and on hospitalization. In the 1990s, calcium channel 264 
blockers were the first-choice antihypertensive drugs in Japan. A previous study showed 265 
that survivors of coronary heart disease who took calcium channel blockers had an 266 
excess risk of total mortality, with plausible explanations including the established 267 
proischemic effect, negative inotropic effects, marked hypotensive effect, and 268 
prohemorrhagic effects of these drugs [15]. Assuming these effects may be broadly 269 
general, they may in part explain our finding of excess risk of CVD mortality associated 270 
with the aggressive treatment of hypertension. Third, we do not have patient data on 271 
hypertension-associated end organ damage such as might be provided by 272 
electrocardiograms, echocardiograms, or ultrasound imaging of the carotid arteries, 273 
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which may mediate the risk of CVD mortality. Fourth, the number of cardiovascular 274 
deaths was small—especially among patients treated for hypertension—although the 275 
present study was large for an Asian cohort study of BP-CVD associations stratified by 276 
treatment. Lastly, the results are based on mortality from CVD rather than its incidence, 277 
which could possibly result in reduced accuracy of diagnosis. In Japan, specification of 278 
underlying causes of death is reported to be reasonable accurate [16,17], although 279 
inaccurate in some instances (eg out of hospital sudden deaths of unspecified origin). 280 
Such misclassification of cardiovascular deaths could differ by BP category, meaning 281 
that our results would be biased. 282 
In conclusion, our results suggest that higher BP categories are linearly and 283 
positively associated with risk of CVD mortality among patients not treated with 284 
antihypertensive medication. However, among treated individuals with optimal and 285 
normal BP levels, we found an excess risk of mortality from total stroke and total CVD 286 
compared with treated individuals with high-normal BP. The present observation 287 
highlights the importance of careful monitoring of the BP and comorbidities of patients 288 
already treated for hypertension who exhibit lower BP levels. 289 
 290 
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Figure legend 301 
Crude mortality rates from total cardiovascular disease according to blood pressure 302 
categories among participants with or without treatment for hypertension.  303 
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Systolic Diastolic Antihypertensive Current Current Total Body mass Diabetes
Blood pressure No. of Age Men blood blood medication smoker drinker cholesterol index mellitus
category participants (%) pressure pressure (%) (%) (%) (mmol/L) (kg/m2) (%)
(mmHg) (mmHg)
Total
 Optimal 5717 53 28 109 67 3 24 37 4.98 21.9 2.5
 Normal 5771 55 35 122 74 6 22 40 5.08 22.8 2.5
 High normal 5740 57 38 132 79 9 22 40 5.15 23.2 3.0
 Grade 1 hypertension 7349 59 40 144 86 18 22 42 5.19 23.8 3.6
 Grade 2-3 hypertension 3151 61 43 167 95 31 22 43 5.23 24.3 4.1
No medication use
 Optimal 5316 53 28 109 67 0 24 37 4.97 22.0 2.2
 Normal 5178 55 36 122 75 0 22 40 5.07 22.8 2.0
 High normal 4968 57 38 132 79 0 22 40 5.14 23.2 2.4
 Grade 1 hypertension 5649 58 41 144 86 0 21 42 5.19 23.7 2.8
 Grade 2-3 hypertension 2042 60 44 166 95 0 22 43 5.22 24.3 3.1
Antihypertensive medication use
 Optimal 85 61 26 111 68 100 23 39 5.01 23.3 7.9
 Normal 265 62 27 123 75 100 19 37 5.19 24.0 6.2
 High normal 484 62 36 133 78 100 19 41 5.22 23.9 7.3
 Grade 1 hypertension 1345 62 35 146 85 100 21 41 5.22 24.1 6.8
 Grade 2-3 hypertension 985 62 41 169 95 100 21 40 5.27 24.2 6.5
TABLE 1 Age- and sex-adjusted baseline characteristics according to blood pressure category.
Blood pressure category was defined as follows: optimal =systolic blood pressure less than 120 mmHg and diastolic blood pressure less than 80 mmHg; normal =120-129 mmHg and/or
80-84 mmHg; high normal =130-139 mmHg and/or 85-89 mmHg; Grade 1 hypertension =140-159 mmHg and/or 90-99 mmHg; Grade 2-3 hypertension =at least 160mmHg and/or 100
Blood pressure Person years No. of Crude HR1* 95%CI HR2* 95%CI
category (PY) deaths  death rate 
(/1000PY)
Total
 Optimal 96,836 148 1.53 0.84 (0.69-1.03) 0.85 (0.69-1.04)
 Normal 96,176 214 2.23 0.95 (0.80-1.14) 0.96 (0.81-1.15)
 High normal 94,711 274 2.89 1.00 1.00
 Grade 1 hypertension 115,434 533 4.62 1.32 (1.14-1.53) 1.26 (1.09-1.46)
 Grade 2-3 hypertension 46,643 308 6.60 1.67 (1.42-1.97) 1.55 (1.31-1.84)
No medication use
 Optimal 89,893 118 1.31 0.81 (0.65-1.02) 0.77 (0.61-0.97)
 Normal 86,169 163 1.89 0.89 (0.73-1.09) 0.88 (0.71-1.08)
 High normal 82,260 212 2.58 1.00 1.00
 Grade 1 hypertension 89,446 337 3.77 1.20 (1.01-1.42) 1.19 (1.00-1.42)
 Grade 2-3 hypertension 30,839 188 6.10 1.62 (1.33-1.98) 1.61 (1.32-1.97)
Antihypertensive medication use
 Optimal 1,333 14 10.50 2.34 (1.27-4.31) 2.31 (1.25-4.27)
 Normal 4,119 33 8.01 1.69 (1.06-2.68) 1.68 (1.05-2.69)
 High normal 7,410 40 5.40 1.00 1.00
 Grade 1 hypertension 19,965 159 7.96 1.58 (1.12-2.24) 1.56 (1.10-2.22)
 Grade 2-3 hypertension 13,771 110 7.99 1.63 (1.13-2.35) 1.63 (1.13-2.36)
Blood pressure category was defined as follows: optimal =systolic blood pressure less than 120 mmHg and diastolic blood pressure less than 80 mmHg; normal =120-
129 mmHg and/or 80-84 mmHg; high normal =130-139 mmHg and/or 85-89 mmHg; Grade 1 hypertension =140-159 mmHg and/or 90-99 mmHg; Grade 2-3
hypertension =at least 160mmHg and/or 100 mmHg, respectively.
* HR1: Stratified by area and adjusted for age and sex; HR2: further adjusted for body mass index, serum total cholesterol levels, history of diabetes, smoking status
and alcohol intake.
Total cardiovascular disease
1.84 (1.20-2.81) 1.83 (1.19-2.81)
TABLE 2.  Multivariable hazard ratios and 95% confidence intervals of cardiovascular disease mortality.
0.90 (0.77-1.06)
0.86 (0.72-1.02)
0.91 (0.78-1.07)
0.83 (0.69-0.99)
Blood pressure Person years No. of Crude HR1* 95%CI HR2* 95%CI No. of Crude HR1* 95%CI HR2* 95%CI
category (PY) deaths  death rate deaths  death rate 
(/1000PY) (/1000PY)
Total
 Optimal to normal 193,012 171 0.89 1.03 (0.81-1.31) 1.04 (0.82-1.32) 60 0.31 0.61 (0.43-0.86) 0.64 (0.45-0.90)
 High normal 94,711 116 1.22 1.00 1.00 67 0.71 1.00 1.00
 Grade 1 hypertension 115,434 253 2.19 1.49 (1.19-1.86) 1.39 (1.11-1.73) 106 0.92 1.06 (0.78-1.44) 1.02 (0.75-1.39)
 Grade 2-3 hypertension 46,643 142 3.04 1.81 (1.41-2.31) 1.65 (1.29-2.13) 71 1.52 1.48 (1.06-2.08) 1.39 (0.99-1.96)
No medication use
 Optimal to normal 176,061 133 0.76 0.98 (0.75-1.29) 0.94 (0.72-1.24) 43 0.24 0.53 (0.36-0.80) 0.54 (0.36-0.81)
 High normal 82,260 89 1.08 1.00 1.00 52 0.63 1.00 1.00
 Grade 1 hypertension 89,446 155 1.73 1.32 (1.01-1.71) 1.30 (1.00-1.69) 74 0.83 1.05 (0.73-1.50) 1.04 (0.73-1.48)
 Grade 2-3 hypertension 30,839 91 2.95 1.83 (1.36-2.46) 1.84 (1.36-2.48) 42 1.36 1.38 (0.91-2.08) 1.32 (0.87-2.00)
Antihypertensive medication use
 Optimal to normal 5,452 22 4.04 1.74 (0.94-3.23) 1.70 (0.91-3.17) 9 1.65 2.30 (0.85-6.22) 2.29 (0.84-6.26)
 High normal 7,410 19 2.56 1.00 1.00 7 0.94 1.00 1.00
 Grade 1 hypertension 19,965 82 4.11 1.72 (1.04-2.85) 1.67 (1.01-2.78) 27 1.35 1.43 (0.62-3.29) 1.41 (0.61-3.27)
 Grade 2-3 hypertension 13,771 49 3.56 1.60 (0.94-2.73) 1.57 (0.91-2.68) 26 1.89 1.79 (0.77-4.16) 1.79 (0.76-4.19)
* HR1: Stratified by area and adjusted for age and sex; HR2: further adjusted for body mass index, serum total cholesterol levels, history of diabetes, smoking status and alcohol
intake.
Blood pressure category was defined as follows: optimal to normal =systolic blood pressure less than 130 mmHg and diastolic blood pressure less than 85 mmHg; high normal =130-
139 mmHg and/or 85-89 mmHg; Grade 1 hypertension =140-159 mmHg and/or 90-99 mmHg; Grade 2-3 hypertension =at least 160mmHg and/or 100 mmHg, respectively.
Supplemental table.  Multivariable hazard ratios and 95% confidence intervals of mortality from stroke and coronary heart disease.
Stroke Coronary heart disease
                 
